19 December 2024
Functionalized single-domain antibodies detecting receptor clusters on cancer cells
Using a combination of luminescent and fluorescent sdAbs, this recent preprint describes the detection of endogenous CXCR4 clusters by BRET. This receptor clustering is increased upon enhanced expression in cancer cells and has been linked to cancer progression.
Read more
18 December 2024
Successful PhD defense of our scientist Stephanie Mareike Anbuhl
Stephanie did her PhD at QVQ as part of the Marie-Curie ITN ONCORNET2.0 in close collaboration with the group of Martine Smit at the VU. In her PhD thesis “Nanobody formats and conjugates detecting, modulating, and targeting CXCR4”, she described the functionalization of sdAbs for various applications. These modified sdAbs were used to investigate the role of the chemokine receptor CXCR4 in cancer. Last week, 4 years of work were concluded with a great defense, that the whole QVQ team was happy to attend.
Read more
28 November 2024
Introducing QSyLi: QVQ’s unique synthetic single-domain antibody (sdAb) library!
Built with 15+ years of sdAb experience, QSyLi combines the diversity of an entire VHH germline with cutting-edge nature-inspired diversification. Designed to accelerate discovery, QSyLi eliminates immunization while enabling exploration of non-immunogenic and toxic targets.
Read more
19 November 2024
QVQ at the GPCR Forum Conference
On November 25th, Stephanie Anbuhl will represent QVQ at the 1st edition of the virtual conference of the GPCR Forum. As one of the invited speakers, Stephanie will present her PhD work on single-domain antibodies targeting the class A GPCR CXCR4. The GPCR forum brings together the global community of GPCR networks. QVQ actively participated as a partner in the Marie Curie International Training Network ONCORNET2.0 focused on the GPCRs CXCR4 and ACKR3.
Read more
12 November 2024
QVQ at the NVF autumn meeting
On Nov 22nd, our scientist Stephanie Anbuhl will present in Session 4, entitled ‘New modes of drug activity’ on the NVF Autumn Meeting in Oss.
The meeting is organized by NVF, Nederlandse Vereniging voor Farmacologie – Dutch Pharmacological Society.
Read more
10 November 2024
QVQ at Kadans Innovation Summit
QVQ’s CEO Dr. Edward Dolk will be joining the Kadans Innovation Summit on the 13th and 14th of November in London to meet leading researchers, entrepreneurs, and innovators from the Europe-wide Kadans science clusters.
Read more
08 November 2024
Discover the applications of our fluorescent single-domain antibodies
Our recent application note highlights the advantages of fluorescent single-domain antibodies (sdAbs) in fluorescence-based technologies and advanced imaging.
Due to their small size, labeled sdAbs have a small linkage error leading to robust signals and improved resolution. They are also cleared quickly from the bloodstream and have enhanced tissue penetration leading to good signal-to-noise ratios.
Read more
01 November 2024
QVQ at PEGS Europe in Barcelona
Dr. Matti Pronker will be attending the 16th PEGS Europe Protein & Antibody Engineering Summit in Barcelona from the 5th to the 7th of November.
Matti will present his poster on the high resolution structure of the FLAG peptide in complex with the M2 anti-FLAG antibody. Besides that he will be available for all your single domain antibody engineering questions.
Read more
01 November 2024 Date Year
QVQ at BIO Europe
Next week, our CSO Dr. Raimond Heukers will be present at the BIO-Europe, Europe’s premier partnering event. (November 4-5, Stockholm, Sweden). You can schedule a meeting with Raimond to discuss QVQ’s single-domain antibody services.
Read more
10 October 2024
QVQ partners with DataChaperone
Being a CRO, service is at the core of everything we do. From this, properly processed and analyzed data-packages are important deliverables. QVQ has partnered with DataChaperone to take data analysis and reporting workflows to the next level.
Read more
24 September 2024
New anti-CD9 sdAbs prevent HIV-1 replication
ogether with fantastic collaborators at the Amsterdam University Medical Center, in particular Jeffrey Umotoy and Steven de Taeye, we have generated a set of new single-domain antibodies against the challenging tetraspannin (4TM domains) CD9 described in this recent publication.
Read more
03 July 2024
QVQ at the ULLA Summer School
On Friday July 5th 2024, our CSO Raimond Heukers, will be at the ULLA summerschool in Leiden, to take an international group of pharmaceutical science researchers (MSc, PhD and postdocs) into the wonderful world of single domain antibodies (sdAbs).
Read more
24 June 2024
sdAbs binding and inhibiting complement factor C5
Our single domain antibodies (sdAbs) Q101c/Q102c detect and inhibit complement factor C5.The two single domain antibodies recently published are available as products Q101c and Q102c. Both sdAbs recognize C5 and its R885H variant and inhibit C5 cleavage, as described in this JBC paper by Eva Struijf et al.
Read more
24 Jun2 2024
Anti-Siglec1 sdAbs as targeting ligands on liposomes
We would like to congratulate our partners from the CanNanoVac consortium, the lab of Joke den Haan, with their latest publication on targeting Siglec1 with sdAb-decorated liposomes. This work not only illustrates the application of sdAbs as targeting ligands on liposomes, it also showcases QVQs ability to generate lead molecules against heavily glycosylated targets.
Read more
24 June 2024
Vacation Listening Tip: Discover Facts and Science with Stuff You Should Know podcast!
Looking for something interesting to listen to while you unwind on vacation? Josh Clark and Chuck Bryant of the Stuff You Should Know podcast have you covered! In a recent episode, they delve into the history and funny facts of camelids, with a special focus on llamas.
Read more
20 June 2024
Dream3D lab led by Anne Rios describes a new screening platform for fluorescence-guided surgery (FGS) probes
Multispectral imaging of 3D patient-derived organoids not only generates beautiful images but also allows for the identification of potential new targets and detection probes to recognize tumor tissue during surgery.
Read more
XX Date Year
Q123, a new product binding atypical chemokine receptor 3 (ACKR3) as neutral antagonist
Q123, also known as VUN701, a single domain antibody binding human atypical chemokine receptor 3 (aka CXCR7) with nanomolar affinity, is now available for research use.
Read more
14 March 2023
NanoB2 for assessing binding of ligands to drug targets
In a collaborative project, researchers at QVQ (Stephanie Mareike Anbuhl and Raimond Heukers), VU Amsterdam (Martine Smit lab) and University of Nottingham (Laura Kilpatrick and Steve Hill) have developed a novel approach using labeled VHH to easily assess and quantify binding of ligands to different drug targets.
Read more
01 March 2023
Stephanie Anbuhl wins poster prize on the annual MCCB KNCV meeting in Lunteren
On Thursday the 30th of March 2023, our talented early-stage researcher (ESR) within the ITN project ONCORNET2.0, Stephanie Mareike Anbuhl , presented her poster on the reformatting of improved CXCR4-targeting single domain antibodies for biophysical detection methods on the annual meeting of the Medicinal Chemistry & Chemical Biology (MCCB) division of the Royal Netherlands Chemical Society (KNCV) in Lunteren.
Read more
15 March 2023
Anti-NCAM1 single domain antibody on the cover of Nature Protocols (blue color).
Big thanks to the group led by Anne Rios, who did an excellent job with establishing the mLSR-3D method for multispectral confocal 3D imaging.
This nicely illustrates the excellent organ penetration of single domain antibodies and its suitability for imaging
Read more
26 August 2022
REACT: HIV reactivation and targeted removal by gene editing
QVQ has intensified its collaboration with the research group of Monique Nijhuis (Translational Virology, UMCU). The REACT project, part of Health Holland TKI-LSH, will investigate possible utilization of our anti-HIV single domain antibody products with mRNA containing lipid nanoparticles (LNPs).
Read more
22 June 2022
Stop the no. 1 elephant killer!
Elephant Endotheliotropic Herpes Virus (EEHV) is the most common cause of death among young elephants.
To aid the development of new detection agents and therapeutic intervention strategies, QVQ will contribute its lead-development to the crowdfunding project “Stop the no. 1 elephant killer!” lead by Utrecht University professors Victor Rutten and Xander de Haan.
Read more
22 June 2022
VHH-Fc fusion constructs show enhanced potency in blocking HIV
Congrats to our Target2Cure collaborators, among which PhD student Angela Schriek and under the supervision of Marit van Gils and Steven de Taeye (AUMC) for having published a nice study in Frontiers in Immunology. Schriek et al. describe the development of QVQ’s anti-HIV-1 single domain antibody products Q1 (J3), Q8 (2E7) and (Q9) 1F10 into various multivalent and Fc-fused constructs.
Read more
22 June 2022
Vimentin for cancer therapy
Congrats to the team lead by professor Arjan Griffioen for their excellent study on targeting extracellular vimentin for cancer therapy. This study also features our anti-vimentin product Q60c, a single domain antibody that suits well for detection and microscopy.
Read more
25 January 2023
Candidalysin causes C. albicans-associated haemolysis
Candida albicans is an opportunistic yeast naturally occurring on our body. This yeast can become pathogenic causing candidiasis. Candidalysin, a peptide toxin secreted by the fungus, is involved in Candida becoming pathogenic the mediates its translocation through intestinal epithelium causing serious infections.
Read more